Peptide Profile
DSIP
Neuropeptide · Nonapeptide
CLINICAL DEVELOPMENT STAGE:
Not Established
DSIP is a small neuropeptide originally investigated for its possible role in sleep regulation. Experimental and human studies have examined its effects on sleep architecture, sleep efficiency, circadian regulation, stress-related signaling, and neuroendocrine pathways. Findings across human sleep studies have been inconsistent, and DSIP has not been established as a clinically validated sleep therapy.
Compound Overview
Molecular Formula
C₃₅H₄₈N₁₀O₁₅
Molecular Weight
848.8 g/mol
CAS Number
62568-57-4
Classification
Neuropeptide · Nonapeptide
Regulatory Status
DSIP is not an FDA-approved drug and does not have an established approved therapeutic indication. Historical human research has investigated its effects on sleep and neuroendocrine regulation, but the available evidence has not established DSIP as a clinically validated treatment for insomnia or other sleep disorders.
Targets / Receptors
No specific receptor definitively established; proposed activity involves GABAergic, glutamatergic, serotonergic, and neuroendocrine signaling pathways.
Research Focus
Sleep-wake regulation and sleep architecture; circadian and chronobiological signaling; stress-response and hypothalamic-pituitary-adrenal axis regulation; neuroendocrine signaling; and experimental models of insomnia, arousal, and daytime vigilance. Human studies have produced mixed findings regarding the magnitude and clinical significance of DSIP’s effects on sleep.
Mechanism of Action
DSIP’s precise molecular mechanism remains incompletely characterized. Research has associated the peptide with modulation of sleep-related electrophysiological activity, neurotransmitter signaling, circadian patterns, and neuroendocrine function. Rather than acting through a single well-established receptor, DSIP appears to influence multiple regulatory systems involved in sleep-wake physiology and stress-related signaling.
Research Evidence
Delta sleep-inducing peptide (DSIP) has been investigated in both experimental models and human clinical studies, with much of the published human research focusing on sleep regulation and chronic insomnia. Early controlled studies reported changes in sleep-related measures including total sleep time, sleep onset, sleep efficiency, nighttime awakenings, and sleep architecture. In a small double-blind crossover study of healthy volunteers, DSIP was associated with increased sleep during the post-administration observation period and improvements in several measures of subsequent nighttime sleep.
Clinical studies in individuals with chronic insomnia produced less consistent findings. Some placebo-controlled investigations reported improvements in nighttime sleep efficiency, daytime alertness, performance, or normalization of disturbed sleep patterns following repeated administration. Other controlled studies found only modest effects. One trial observed increases in total and NREM sleep but concluded that the overall improvement was of little clinical significance, while another found higher sleep efficiency and shorter sleep latency but characterized the effects as weak and unlikely to provide major therapeutic benefit.
Beyond sleep, experimental literature has examined DSIP in relation to circadian regulation, electrophysiological activity, neurotransmitter signaling, hormonal and neuroendocrine activity, stress responses, and behavioral regulation. However, these broader effects remain incompletely characterized, and a specific receptor-mediated mechanism for DSIP has not been firmly established.
Overall, DSIP has a history of human investigation rather than being exclusively a preclinical research peptide. However, the clinical evidence is derived largely from small studies conducted several decades ago, results have been inconsistent across trials, and the available research has not established DSIP as a validated treatment for insomnia or other sleep disorders.
Safety & Limitations
Human safety data for DSIP are limited and are derived primarily from small, older clinical studies. These studies do not provide the scale, duration, or methodological consistency needed to establish a comprehensive safety profile.
The available research has not established standardized dosing, long-term safety, pharmacokinetics, drug-interaction profiles, or safety in specific populations. Evidence regarding DSIP’s effects on sleep is also inconsistent, with controlled studies reporting variable and sometimes clinically modest effects.
DSIP does not have an established therapeutic indication or a well-defined molecular receptor, and its mechanisms of action remain incompletely characterized. Much of the published human research dates from the 1970s through the 1990s, with limited modern clinical investigation available to confirm earlier findings.
Key References
Zhang XG, Wang WN, Zhang CS, et al. (2017). Expression and purification of delta sleep-inducing peptide fused with protein transduction domain and human serum albumin in Pichia pastoris. Protein & Peptide Letters.
Kovalzon VM, Strekalova TV. (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry.
Schneider-Helmert D, Kumar A. (1995). Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides.
Schneider-Helmert D, Schoenenberger GA. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology.
Schneider-Helmert D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Neuropsychobiology.
Schneider-Helmert D, Schoenenberger GA. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy, and Toxicology.
Last scientifically reviewed: 10/08/2026